CEVR analyzes the value of strategies to improve health and health care.

About Us

News

Do Medicare’s IPAY 2027 Negotiated Drug Prices Reflect Value For Money?

CEVR offers its thoughts on CMS’s most recent round of negotiated drug prices and whether they align with value.Commentary: Do Medicare’s IPAY 2027 ne...

Read more December 11, 2025

The Best Books I Read in 2025

By Peter Neumann, ScD, Director I’m not sure why, but I read more novels than usual this year. Perhaps it was in defiance of those articles I saw lame...

Read more December 8, 2025

The ‘Pharm-To-Table’ Movement For Prescription Drugs: Promising Or Performative?

A growing number of drugmakers are rolling out “pharm-to-table” initiatives to sell drugs directly to patients at lower costs. However, the extent to ...

Read more December 5, 2025

View All News Items

Events

CEVR Participation at ISPOR EU 2025

November 10–12, 2025

CEVR Health Policy Seminar with Boshen Jiao, PhD, MPH

2:30–3:30 on November 5, 2025

CEVR Health Policy Seminar with Carl Asche, PhD, MSc

2:00–3:00 on September 30, 2025

View All Events

Recent Publications

AJMC

Communication of Launch Prices by Drug Companies, 2022-2024

View publication

December 15, 2025

Health Affairs Forefront

Do Medicare’s IPAY 2027 Negotiated Drug Prices Reflect Value For Money?

View publication

December 11, 2025

Journal of Neuromuscular Disease

US Health Plan Coverage of Neuromuscular Disease Therapies: An Assessment of Policy Availability and Restrictions

View publication

December 9, 2025

Health Affairs Forefront

The ‘Pharm-To-Table’ Movement For Prescription Drugs: Promising Or Performative?

View publication

December 5, 2025

Medical Decision Making

When Do Published Cost-Effectiveness Analyses Include Societal Costs? An Empirical Analysis, 2013–2023

View publication

December 1, 2025

Health Affairs Scholar

The Unintended Consequences of the Inflation Reduction Act on Biosimilar Market Incentives and Medicare Savings

View publication

November 19, 2025

The Journal of Pediatrics

Rapid Genome Sequencing Compared with a Gene Panel in Critically Ill Infants with a Suspected Genetic Disorder: An Economic Evaluation

View publication

October 31, 2025

JAMA

Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies

View publication

September 29, 2025

View All Publications

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.

CEA Registry

The CEA Registry is a comprehensive database of 9,080 cost-utility analyses on a wide variety of diseases and treatments.

Global Health CEA Registry

The GH CEA Registry is the first comprehensive database to compile articles utilizing the “cost-per-DALY averted” metric to measure the efficacy of health interventions.

SPEC Database

The Specialty Drug Evidence and Coverage (SPEC) Database is a new data resource developed with the goal of providing an empirical basis to commercial payer specialty drug coverage.

Learn About Our Databases